Amelioration of αLPHA-synuclein aggregation and motor behavior deficits by apocyanin in intranigral lipopolysaccharide induced animal model of Parkinson’s disease
Objective: The present study evaluated the therapeutic potentials of apocyanin for the treatment of neurobehavioral consequences in LPS induced PD model. Background: Parkinson's disease (PD),…Neuroprotection effect of an endogenous amine, 1MeTIQ against disturbances in dopamine release induced by the neurotoxin, 6-OHDA: In vivo microdialysis study
Objective: The aim of the present study was to investigated using microdialysis methodology the impact of 1MeTIQ on the disturbances of in vivo dopamine release…Neuroprotective and antidepressant-like effects of the endogenous amines from tetrahydroisoquinoline group TIQ and 1MeTIQ in the animal model of depressive disorder: Behavioral and neurochemical studies in the rat
Objective: For the purpose of estimation neuroprotective and antidepressant-like effects of the endogenous amines 1,2,3,4-tetrahydroisoquinoline (TIQ) and its close methyl derivative, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) in the…Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson’s disease
Objective: To Evaluate:prepared a MPTP/p induced mouse subacute model of PD, and explore the modulatory effect of H2S on monoamine and amino acid neurotransmitters in…AntiParkinsonian effects of AG-0029 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the motor functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of AG-0029. Background: Parkinson's disease (PD), in which there is widespread degeneration…Cognitive effects of AG-0029 in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the cognitive functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of AG-0029. Background: Parkinson's disease (PD), in which there is widespread degeneration…Cognitive effects of pramipexole in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the cognitive functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of Pramipexole (PPX). Background: Parkinson's disease (PD) is characterized by both motor…Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke
Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…Autophagic modulation by rosuvastatin prevent rotenone induced neurotoxicity as an in vitro model of Parkinson’s disease
Objective: We investigated effects of statin on autophagy markers and evaluated the neuroprotective effect of rosuvastatin from rotenone induced neurotoxicity. Background: Recently, autophagy pathway is…Targeting PDE7 by the small molecule S14: A potential disease-modifying Parkinson�s disease therapy ready to start clinical trials
Objective: The main goal of this work is the regulatory chemical, pharmaceutical and toxicological development of S14, a new therapeutic class for the potential treatment…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.